A New Era in Metabolic Treatment
Glucagon-like peptide-1 (GLP-1) receptor agonists have fundamentally changed the landscape of metabolic medicine. Originally developed for type 2 diabetes management, these medications have demonstrated remarkable efficacy in weight management, cardiovascular risk reduction, and even neuroprotection.
The mechanism is elegant: GLP-1 receptor agonists mimic the natural incretin hormone GLP-1, which is released by the gut after eating. They stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and act on brain centres that regulate appetite and satiety.
Semaglutide: The Game Changer
Semaglutide, marketed as Ozempic for diabetes and Wegovy for weight management, has captured global attention. In the landmark STEP trials, participants lost an average of 15–17% of their body weight over 68 weeks. For Canadians, Health Canada approved Wegovy in 2023, though access and coverage remain significant challenges.
The cardiovascular benefits are equally compelling. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity but without diabetes, establishing semaglutide as more than just a weight-loss drug.
Tirzepatide: The Dual Agonist
Tirzepatide (Mounjaro/Zepbound) takes the concept further by targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The SURMOUNT trials showed weight loss of up to 22.5% — approaching what was previously only achievable through bariatric surgery.
What Canadians Should Know
Access to GLP-1 receptor agonists in Canada varies by province. While most provincial formularies cover these medications for type 2 diabetes, coverage for obesity treatment is inconsistent. The Canadian Obesity Network advocates for broader access, recognizing obesity as a chronic disease requiring long-term pharmacotherapy.
Common side effects include nausea, vomiting, and diarrhea, which typically diminish over time with gradual dose escalation. Serious but rare risks include pancreatitis and potential thyroid concerns, though large-scale studies continue to refine our understanding of the safety profile.
The Future
The pipeline is rich with next-generation molecules. Oral semaglutide formulations are improving, triple agonists (GLP-1/GIP/glucagon) like retatrutide show even greater efficacy, and amylin analogues like cagrilintide are being combined with semaglutide for enhanced results. The metabolic medicine revolution is only beginning.
